Are women with Sjögren's syndrome androgen-deficient?
…, A Bélanger, JM Cermak, R Bérubé, AS Papas… - The Journal of …, 2003 - jrheum.org
OBJECTIVE: We hypothesize that androgen deficiency is a critical etiologic factor in the
pathogenesis of aqueous-deficient and evaporative dry eye in Sjögren's syndrome (SS). We …
pathogenesis of aqueous-deficient and evaporative dry eye in Sjögren's syndrome (SS). We …
Successful treatment of dry mouth and dry eye symptoms in Sjögren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment …
AS Papas, YS Sherrer, M Charney… - JCR: Journal of …, 2004 - journals.lww.com
Background: Sjögren’s syndrome is characterized by the presence of xerostomia and/or
xerophthalmia. Pilocarpine, a muscarinic cholinergic agonist, has been proven to be efficacious …
xerophthalmia. Pilocarpine, a muscarinic cholinergic agonist, has been proven to be efficacious …
The effects of denture status on nutrition
AS Papas, CA Palmer, MC Rounds… - Special Care in …, 1998 - Wiley Online Library
In Part I of this study, the Human Nutrition Research Center of the United States Department
of Agriculture's Nutritional Status Study (NSS) of 691 independently living elderly people …
of Agriculture's Nutritional Status Study (NSS) of 691 independently living elderly people …
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of …
…, M Bombardieri, MG Posch, AS Papas… - The Lancet …, 2020 - thelancet.com
Background Primary Sjögren's syndrome is an autoimmune disease that presents as dryness
of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no …
of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no …
Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults
…, AS Papas, JM Goodson, LA Navalta, S Rogy… - The Journal of the …, 2008 - Elsevier
Background The authors conducted two multicenter, randomized, double-blinded, controlled
Phase III clinical trials to study the efficacy and safety of phentolamine mesylate (PM) in …
Phase III clinical trials to study the efficacy and safety of phentolamine mesylate (PM) in …
Meibomian gland dysfunction in primary and secondary Sjögren syndrome
…, A Sahin, B Arica, Y Liu, WR Kam, AS Papas… - Ophthalmic …, 2018 - karger.com
Purpose: We hypothesized that women with primary (pSS) and secondary Sjögren
syndrome (sSS; with systemic lupus erythematosus [SLE] or rheumatoid arthritis [RA]) have …
syndrome (sSS; with systemic lupus erythematosus [SLE] or rheumatoid arthritis [RA]) have …
Reversal of soft-tissue local anesthesia with phentolamine mesylate in pediatric patients
…, S Rogy, B Rutherford, S Gordon, AS Papas… - The Journal of the …, 2008 - Elsevier
… Papas DMD, PhD 9 , Soft Tissue Anesthesia Reversal Group … Papas and Goodson are
members of the Clinical Advisory Board for Novalar Pharmaceuticals. Drs. Tavares, Gordon and …
members of the Clinical Advisory Board for Novalar Pharmaceuticals. Drs. Tavares, Gordon and …
Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate
Phentolamine mesylate accelerates recovery from oral soft tissue anesthesia in patients
who have received local anesthetic injections containing a vasoconstrictor. The proposed …
who have received local anesthetic injections containing a vasoconstrictor. The proposed …
[PDF][PDF] Longitudinal relationships between nutrition and oral health
AS Papas, CA Palmer, MC Rounds, J Herman… - Ann NY Acad …, 1989 - academia.edu
Poor oral health can profoundly decrease appetite and the ability to eat, which in turn may
lead to poor nutrition. Compromised nutritional status may result in an impaired immune …
lead to poor nutrition. Compromised nutritional status may result in an impaired immune …
The effect of a selective cyclooxygenase‐2 inhibitor (celecoxib) on chronic periodontitis
…, PL Hibberd, M Singh, AS Papas - Journal of …, 2008 - Wiley Online Library
Background: Non‐steroidal anti‐inflammatory agents inhibit the production of cyclooxygenase
(COX) products and can attenuate bone loss. In this double‐masked, placebo‐controlled, …
(COX) products and can attenuate bone loss. In this double‐masked, placebo‐controlled, …